Clinical Trial Goal
To find out if loncastuximab tesirine is safe and works well to treat MZL that has relapsed or is refractory
You may be able to join this trial if you:
- Are 18 years old or older
- Have MZL that has relapsed or is refractory
- Do not have diffuse large B-cell lymphoma (DLBCL)
- Do not have lymphoma cells in your brain or spinal cord
- Have not had an allogeneic (cells from a donor) blood or marrow transplant (BMT) in the last 6 months
- Have not had an autologous (your own cells) BMT in the last 3 months
- Do not have active graft versus host disease (GVHD)
- Have not been treated with a drug that targets CD19. Your doctor can tell you this
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
Loncastuximab is a monoclonal antibody-drug conjugate that targets CD19 on certain cells.
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
You’ll get treatment in cycles that last 3 weeks. In each cycle, you'll get:
- Loncastuximab tesirine - Given as intravenous (IV) infusions for up to 3 times. The dose you'll get depends on when you start the trial and how safe it has been
You may continue treatment for 4 1/2 months. You'll have scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 2 years.
The Food and Drug Administration (FDA) has approved the drug used in this trial. Using it in this way to treat MZL is new and unproven.
The Food and Drug Administration (FDA) has approved the drug used in this trial. Using it in this way to treat MZL is new and unproven.
Locations
City of Hope National Medical CenterRECRUITING
Duarte, California
Johana Carmona, DO, PhD, 626-218-0942, gshouse@coh.org
University of MiamiRECRUITING
Miami, Florida
Lutecia Pereira, PhD, 305-243-6160, lpereira@med.miami.edu
Emory UniversityRECRUITING
Atlanta, Georgia
Jean L Koff, MD, 404-778-0519, jkoff@emory.edu
Vanderbilt UniversityRECRUITING
Nashville, Tennessee
Olalekan Oluwole, MD, 615-936-8422, olalekan.oluwole@vumc.org
Sponsors
collaborator: ADC Therapeutics S.A., lead: University of Miami
